Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1264

Urelumab

Home » Urelumab

Background of Urelumab

CD137 is a costimulatory member of the TNF receptor superfamily that is expressed on a variety of immune cells following activation, including T cells, dendritic cells, and natural killer cells. Urelumab (BMS-663513, Bristol-Myers Squibb) is an agonist, fully human mAb, engineered as an IgG4 to reduce binding to Fc receptors with a hinge mutation (S228P) to improve stability. In preclinical studies, urelumab enhanced IFNγproduction, T-cell survival, and the cytolytic activity of antigen-specific T cells, as expected for an antibody with costimulatory activity.

Specifications

Catalog Number:
KB-1264
Antibody Name:
Urelumab
Isotype:
Human IgG4-S228P, kappa
FC Muations:
S228P
Target:
CD137
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
ELISA
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Sznol M, Hodi FS, Margolin K, McDermott D, Ernstoff M, Kirkwood J, et al Phase I/II study of BMS-663513, a fully-human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. J Clin Oncol 2008; 26:15s(suppl; abstr 3007).
  2. Jure-Kunkel MN, Calarota S, Girit E, Abraham R, Balimane P, Price K, et al Functional characterization of fully human anti-CD137 antibodies. In:Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1–5; Washington, DC. Philadelphia, PA: AACR; 2006. Abstract nr 4759.
  3. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012; 61:1721–33.